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Summary
Standard surgical aortic valve replacement with a biological prosthesis remains the treatment of choice for low- and mid-risk elderly
patients (traditionally >65 years of age) suffering from severe symptomatic aortic valve stenosis or insufﬁciency, and for young patients
with formal contraindications to long-lasting anticoagulation. Unfortunately, despite the fact that several technical improvements have
noticeably improved the resistance of pericardial and bovine bioprostheses to leaﬂet calciﬁcations and ruptures, the risk of early valve
failure with rapid degeneration still exists, especially for patients under haemodialysis and for patients <60 years of age at the time
of surgery. Until now, redo open heart surgery under cardiopulmonary bypass and on cardioplegic arrest was the only available thera-
peutic option in case of bioprosthesis degeneration, but it carried a higher surgical risk when elderly patients with severe concomitant
comorbidities were concerned. Since a few years, the advent of new transcatheter aortic valve procedures has opened new horizons
in cardiac surgery and, in particular, the possibility of implanting stented valves within the degenerated stented bioprosthesis, the so-
called ‘valve-in-valve’ (VinV) concept, has become a clinical practice in experienced cardiac centres. The VinV procedure represents a
minimally invasive approach dedicated to high-risk redo patients, and published preliminary reports have shown a success rate of 100%
with absence of signiﬁcant valvular leaks, acceptable transvalvular gradients and low complication rate. However, this procedure is not
riskless and the most important concerns are about the size mismatch and the right positioning within the degenerated bioprosthesis.
In this article, we review the limited available literature about VinV procedures, underline important technical details for the positioning
and provide guidelines to prevent valve–prosthesis mismatch comparing the three sizes of the only commercially available transapical
device, the Edwards Sapien™, with the inner diameter of three of the most commonly used stented bioprostheses.
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INTRODUCTION
Aortic valve stenosis (AS) is the most frequent valvular heart
disease in developed countries, and affects the elderly population
[1, 2]. Aortic valve replacement (AVR) with cardiopulmonary
bypass, cardioplegic arrest and aortic cross-clamping through a
median sternotomy, an upper mini-sternotomy or a right mini-
thoracotomy, represents, for the time being, the treatment of
choice for severe AS, and provides good operative outcomes and
long-term results [3, 4]. Patients also affected by regurgitant aortic
valves or by aortic endocarditis are eligible for standard AVR and,
following the standard international guidelines, all patients over
the age of 65 years at the time of surgery, or younger patients
with contraindications to the long-lasting anticoagulation therapy,
are ideal candidates for the implantation of a biological prosthesis.
In particular, stented bioprostheses, both pericardial and
porcine, do not require anticoagulation, are easy to be implanted
with a standardized and reproducible surgical technique, have
excellent haemodynamic performances and, thanks to the
improved treatments (anticalciﬁcation) and construction, have an
increased longevity [5–8]. However, despite all attempts to decrease
the incidence of leaﬂet calciﬁcations and structural failure, early
degeneration can occur (especially in young patients and in
patients under haemodialysis) and, nowadays, the treatment of
choice for the replacement of a malfunctioning bioprosthesis is a
cardiac reoperation with a mortality rate that lies below 5% in the
latest series [9–13]. Unfortunately, despite the fact that the redo
itself is not an independent risk factor for re-AVR, redo valve
surgery in the elderly high-risk patient with severe comorbidities is
still related to a higher operative risk with increased hospital mor-
tality and postoperative complication rate [13–15].
Thus, the transcatheter aortic valve procedure plays a key role,
and the possibility of implanting stent-valves into failed stented
bioprostheses, the ‘valve-in-valve’ (VinV) concept, represents an
alternative for redo high-risk patients [16–19]. As regards to the
transapical access for aortic VinV procedures, we are observing a
burden in the number of performed cases, and experienced
centres employ this technique routinely for selected cases.
Moreover, a few VinV case reports and limited series have
appeared in the literature showing a good outcome with low
transvalvular gradients, no major leaks and few postoperative
complications [18]. Nevertheless, the risk of valve–prosthesis
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mismatch still exists [20]. In this article, we underline important
details for transapical VinV in stented bioprostheses, we expose
the review of clinical results and haemodynamic parameters
and, in order to avoid the mismatch, we suggest guidelines
for the sizing comparing the transapical Sapien™ platform with
three common stented bioprostheses.
TECHNICAL ASPECTS
Edwards Sapien™
The only available transapical stent-valve is the Sapien™
(Edwards Lifesciences, Irvine, CA, USA) (Fig. 1A), a balloon-
expandable stent with an inner bovine pericardial valve. It is
available in two sizes, 23 and 26 mm, and is inserted using the
Ascendra™ delivery system. Recently, a new XT generation
(Fig. 1B), with the Ascendra II delivery system, was launched with
some innovations such as the cobalt–chromium stent, a smaller
delivery system (22F and 24F), a semi-closed leaﬂet proﬁle and a
bigger 29 mm size (for transapical).
Patients selection
Symptomatic patients with degenerated bioprostheses present-
ing with severe comorbidities are candidates for transapical
aortic VinV (high-risk). The logistic EuroSCORE and the STS score
calculate the predicted mortality, and the inclusion and exclu-
sion criteria are similar to those proposed for standard TAVI [21,
22]. However, due to the fact that during VinV procedures in
stented bioprostheses the ﬁxation of the valve is guaranteed by
radial forces applying against the rigid ring (unlike in standard
TAVI where heavy calciﬁcations of the annulus and valve are
required for ﬁxation), not only stenosis but also intra-prosthetic
incompetence due to leaﬂet ruptures or tears is treatable with
this approach. Bioprosthetic endocarditis remains a formal con-
traindication because the infected bioprosthetic leaﬂets are not
removed during the procedure. The presence of a concomitant
mitral prosthesis seems not to interfere with aortic VinV, and
candidates for VinV procedures require neither speciﬁc preo-
perative exams nor cardiac imaging and do not even require an
injected cardiac scan to measure the annulus, given that the size
of the valve is pre-determined by the size of the bioprosthesis.
Sizing (valve–prosthesis match)
During the implantation of a stent-valve within a stented bio-
prosthesis, there is a risk of severe mismatch, creating either a
relevant transvalvular gradient, when the oriﬁce of the bio-
prosthesis is too small compared with the stent-valve diameter,
or a stent-valve embolization when the stent-valve is too small
compared with the inner size of the prosthesis.
In order to identify which stent-valve ﬁts perfectly into differ-
ent sizes of a given stented aortic bioprosthesis, we measured
the internal diameter of three common aortic bioprostheses,
from the labelled size of 21–25 mm, using the Hegar cervical
dilators (ranging from 15 to 27 mm). Then, we suggested which
of the sizes of the currently available Sapien™ valve is the most
indicated for aortic VinV when a degenerated St Jude Medical
Trifecta™, Sorin Biomedica Mitroﬂow™ or Edwards Perimount™
Magna Ease is in place (Table 1).
In order to simplify the decision-making process, we can state
that all 23 mm Sapien™ stent-valves implanted into the 21 mm
size stented bioprosthesis are at risk for high postoperative trans-
valvular gradient (expected gradient >30 mmHg in clinical prac-
tice) [18, 20]. Thus, we suggest careful consideration of this
option only for inoperable elderly patients with limited body
surface areas (<1.8 m2). Concerning the 23 and 25 mm sizes, the
measured inner diameters can easily accept the 23 mm Sapien™.
In the end, the 27 mm Sorin Mitroﬂow™ can accept a 23 mm
Sapien™, whereas the 27 mm Trifecta™ and Perimount™ require
the implantation of a 26 mm Sapien™ valve.
Imaging
TAVI requires high-quality imaging based on echocardiography
and angiography. However, during VinV procedures, angiogra-
phies are almost no longer necessary and the procedure can be
performed under transoesophageal echocardiographic and
ﬂuoroscopic control without contrast. Effectively, the positioning
of the ﬂuoroscopic machine on a plane perpendicular to the
aortic valve is very easy and does not require repeated angiogra-
phies, given that the ring of the bioprosthesis is radiopaque
(Fig. 2A). Moreover, during stent-valve positioning, the ring acts
as a landmark and, again, angiographies are not necessary (see
the next section) (Fig. 2B). In regard to postoperative control, the
transoesophageal echocardiogram can conﬁrm good valve pla-
cement and function within the diseased bioprosthesis: if the
Sapien™ is well positioned, peri-prosthetic leaks will not appear
as the stent-valve expands into a prosthetic cylinder without rel-
evant burden calciﬁcations (usually, degenerations and tears
appear in the prosthetic leaﬂets). Fluoroscopy can show the cir-
cumferential stent-valve deployment whereas an angiography
can conﬁrm coronary patency (Fig. 2C and D).
Figure 1: (A) the Edwards Sapien™ valve; (B) the new Sapien™ XT generation
available in three sizes for transapical applications: 23, 26 and 29 mm.
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In conclusion, VinV does not require high doses of contrast
and can be proposed for patients suffering from chronic renal
failure [23].
Positioning
According to the experience obtained by the ﬁrst VinV implan-
ters, we suggest keeping the lower margin of the Sapien™ 2–3
mm below the radiopaque margin of the ring (Fig. 2D). Using
this stratagem, the lateral shape of the Sapien™ remains rec-
tangular or, at least, with the proximal diameter a bit smaller
than the distal diameter (inverted trunk pyramid): in this way,
valve function is preserved without risk of stenosis or malfunc-
tioning. If, on the contrary, the stent-valve is positioned too low,
the resulting lateral clepsydra shape can modify the Sapien™
geometry with the risk of stenosis and early degeneration. To
better describe VinV stent-valve positioning, two drawings in
Figs 3 and 4 explain this mechanism in standard Primount™ and
Mitroﬂow™ valves.
Implantation
Stent-valve implantation follows, basically, the same rules of
standard TAVI. Nevertheless, there is a general consensus in not
performing valvuloplasty before, because of a potential risk of
calcium embolization from the degenerated bioprosthesis.
RESULTS
Table 2 summarizes clinical and haemodynamic data from pub-
lished aortic VinV series with 38 successful transapical procedures
performed in 38 patients with degenerated stented bioprostheses
[24–28]. During our personal clinical experience, we performed
six aortic VinV procedures and, despite the limited experience,
we can conﬁrm that this technique has acceptable postoperative
results. Haemodynamically, there were no leaks and the
measured mean gradient was 18 mmHg. All patients were rapidly
Table 1: Measured inner diameter of three commonly used aortic bioprostheses with the corresponding suggested Sapien™ size
Labelled size
(mm)






Sorin Biomedica Mitroflow™ 21 17.3 17 23a
23 19 19 23
25 21 20 23
27 22.9 22 23
Edwards Perimount™ Magna Ease 21 20 18 23a
23 22 21 23
25 24 22 23
27 26 24 26
St Jude Medical Trifecta™ 21 18.3 18 23a
23 20.3 20 23
25 22.1 22 23
27 24.1 24 26
aThe suggested Sapien™ size will create high transvalvular gradients because of the too small inner diameter of the bioprosthesis. This option must be
carefully considered only for inoperable patients.
Figure 2: Fluoroscopic images from a VinV case: (A) the ﬂuoroscopic machine
is positioned perpendicular to the ring of the bioprosthesis; (B) valve posi-
tioning and implantation are facilitated by the presence of the ring and do
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extubated, they all left the intensive care unit at postoperative
Day 1 and there were no relevant complications. In one case, we
treated a patient with a degenerated 21 mm bioprosthesis and, as
expected, we measured a high transvalvular peak gradient of 35
mmHg. The patient, an 86-year-old lady with a EuroSCORE of
51% and a porcelain aorta, was considered inoperable, and the
VinV procedure was the only available option: in spite of the high
gradient, she left our department without signs of cardiac decom-
pensation. In another similar case with a 21 mm size bioprosth-
esis, Seiffert et al. [27] also implanted a 23 mm Sapien™ valve,
with a transvalvular gradient of 35 mmHg and a good outcome
[27], whereas Silva et al. [20] explanted the Sapien™ and the 21
mm Hankock bioprosthesis 1 year after VinV for progressive dys-
pnoea and a mean gradient of 43 mmHg. Following these ﬁnd-
ings, we do not suggest aortic VinV in the 21 mm bioprosthesis.
Our clinical results are in line with the published literature and
the procedural success rate is 100% in all centres, conﬁrming
that valve positioning and implantation are feasible. However,
despite these good operative results, one patient at extreme sur-
gical risk (EuroSCORE >80%) died within 30 days from low
cardiac output, and this event conﬁrms the high-risk proﬁle of
this subgroup of patients [27].
Concerning the valve sizing, among a total number of 38
Sapien™ valves, 36 were 23 mm and 4 were 26 mm. This trend
conﬁrms our ﬁndings during the measurement of three com-
mercial bioprostheses: the 23 mm Sapien™ ﬁts within the 21
(risk of high gradients), 23 and 25 mm tested bioprostheses, and
also into the 27 mm Sorin Mitroﬂow™, whereas the 26 mm
Sapien™ ﬁts into the 27 mm Perimount™ and Trifecta™.
However, in these ﬁrst reports, the 26 mm Sapien™ was also
employed in one 25 mm Edwards Perimount™, in one 25 mm
CE Porcine and in two 25 mm Medtronic Hancock™, suggesting
that the larger inner diameter of the 25 mm bioprosthesis can
accept both the 23 and 26 mm stent-valves without risk of high
gradients or embolization.
DISCUSSION
Results from limited transapical aortic VinV series suggest that
this technique, dedicated to high-risk patients, guarantees accep-
table transvalvular gradients in 23 and 25 mm degenerated bio-
prostheses with absence of relevant leaks and complications.
VinV in the 21 mm bioprosthesis creates high gradients and
should be considered only in inoperable patients. Thus, a few
topics must be underlined in order to standardize the technique
and facilitate the decision-making process for the sizing.
(i) The procedure does not require a speciﬁc preoperative
cardiac imaging to measure the aortic annulus because the
stent-valve sizing is determined by the inner diameter of the
previously implanted bioprosthesis. We have personally
measured the inner diameter of three commonly used bio-
prostheses, and we can say that our data do not differ from
data given by the industry except for the Edwards Perimount™
Magna Ease where the given diameters are overestimated by
2 mm. Thus, a CT scan can be useful when a doubt exists
about the real internal diameter of a bioprosthesis.
Figure 4: The schematic positioning of a Sapien™ stent-valve within a Sorin
Biomedica Mitroﬂow™ aortic bioprosthesis.
Figure 3: The schematic positioning of a Sapien™ within an Edwards
Perimount™ aortic bioprosthesis.
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(ii) Once the inner diameter is determined, we suggest identify-
ing the ideal stent-valve size that ﬁts into the bioprosthesis.
The 23 mm Sapien™ valve seems to be the most usable size
because it ﬁts into the mostly used stented bioprostheses:
the 23 mm and the 25 mm. The 21 mm size bioprosthesis
can also be treated by VinV, but high gradients are expected
and, then, we strongly encourage the implantation of a
23 mm or a larger bioprosthesis during standard AVRs
because it will allow further VinV options.
(iii) During the procedure, the ring of the bioprosthesis is useful
for ﬂuoroscopy orientation and valve positioning. VinV does
not require high doses of contrast; it may even be per-
formed without angiographies and can be performed in
patients with chronic renal failure.
(iv) There is a consensus among expert implanters to not
perform valvuloplasty before stent-valve implantation (risk
of embolization).
(v) The stent-valve is implanted within the stented bioprosthesis
with the lower margin 2–3 mm below the margin of the ring.
This positioning guarantees correct valve functioning [28].
(vi) Concerning the durability of aortic VinV, we do not yet have
mid-/long-term results because only a few patients have a
follow-up longer than 1 year.
Another concept that should be taken into consideration is
the possibility, as long as big sizes are a guarantee (>23 mm), of
implanting biological bioprostheses in patients younger than 65
years of age: in fact, the risk of early degeneration can be com-
pensated by the absence of long-lasting anticoagulation and by
VinV options. However, bigger clinical series and mid-/long-term
results are necessary before changing the clinical practice.
CONCLUSION
This limited clinical experience conﬁrms that transapical VinV
procedures for degenerated stented bioprostheses do not
require a speciﬁc cardiac imaging (with limited contrast injec-
tions) and guarantee good results with acceptable gradients
(excepting for the 21 mm bioprosthesis) and no major leaks.
Concerning the sizing, the 23 mm Sapien™ seems to be the
most useful stent-valve because it ﬁts within the most widely
used stented bioprostheses: the 23 mm and the 25 mm. In
view of all of these facts, we recommend implanting a large
bioprosthesis (equal or superior to 23 mm diameter) during
standard AVRs in order to prevent size mismatch in case of
VinV.
Conﬂict of interest: none declared.
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